Skip to content

US · NNNN · MEDICAL - INSTRUMENTS & SUPPLIES

Anbio Biotechnology Class A Ordinary Shares (NNNN) intrinsic value and stock valuation

$3.32as of 2026-11-21 · Mkt cap 445.5M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Anbio Biotechnology Class A Ordinary Shares DCF and intrinsic value

InvestorsCraft values NNNN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NNNN’s statements →

Anbio Biotechnology Class A Ordinary Shares Graham Number

Graham Number: $1.50d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Frankfurt am Main, HE 60437 anbio.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$8.65M
20212025
Net income
$6.4M
20212025
Free cash flow
-$-6.74M
20212025
Total equity
$30.2M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$8.65M$8.19M$6.71M$23.5M$4.43M
Operating income$5.77M$2M$1.96M$10.2M$2.46M
Net income$6.4M$2.37M$2.25M$10M$2.54M
EPSd$145.8K$56K$12K$69.6K$25.4K
Operating cash flow-$-6.74M$2.08M$900K$4.45M$4.18M
Capital expenditure$0.00$0.00$0.00-$0.00$0.00
Free cash flow-$-6.74M$2.08M$900K$4.45M$4.18M
Total assets$30.2M$18.9M$15.8M$14M$4.92M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-7.77M-$-11.76M-$-9.69M-$-7.1M-$-4.18M
Total equity$30.2M$17.2M$14.8M$12.6M$2.54M
Cash and short-term investments$11.9M$11.8M$9.69M$8.67M$4.18M
Income statement
20252024202320222021
Revenue$8.65M$8.19M$6.71M$23.5M$4.43M
Cost of revenue$1.1M$2.3M$3.35M$11M$1.89M
Gross profit$7.54M$5.89M$3.36M$12.6M$2.54M
Research and development expenses$200K$450K$130K$200K$0.00
Selling, general and administrative expenses$1.57M$3.44M$1.27M$2.17M$90K
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.78M$3.89M$1.4M$2.37M$90K
Cost and expenses$2.88M$6.19M$4.75M$13.4M$1.97M
Interest income$140K$340K$170K$40K$0.00
Interest expense$0.00$0.00$0.00$10K$0.00
Depreciation and amortization$0.00$0.00$10K$10K$0.00
Ebitda$5.77M$2M$2.27M$10M$2.54M
Operating income$5.77M$2M$1.96M$10.2M$2.46M
Total other income/expenses, net$640K$380K$290K-$-180K$80K
Income before tax$6.4M$2.37M$2.25M$10M$2.54M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$6.4M$2.37M$2.25M$10M$2.54M
Weighted average shares outstanding$43.9M$42.3M$143.9M$143.9M$100M
Weighted average diluted shares outstanding$43.9M$42.3M$187.8M$143.9M$100M
Balance sheet
20252024202320222021
Cash and short-term investments$11.9M$11.8M$9.69M$8.67M$4.18M
Net receivables$3.66M$1.06M$1.88M$0.00$720K
Inventory$0.00$0.00$0.00$350K$0.00
Total current assets$30.2M$18.5M$15.8M$13.9M$4.92M
Property, plant and equipment, net$0.00$0.00$0.00$10K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$390K$60K$20K$0.00
Total assets$30.2M$18.9M$15.8M$14M$4.92M
Accounts payable$0.00$1.63M$830K$1.41M$1.89M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$490K
Total current liabilities$90K$1.73M$990K$1.41M$2.38M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$90K$1.73M$990K$1.41M$2.38M
Common stock$10K$10K$10K$0.00$0.00
Retained earnings$23.6M$17.2M$14.8M$12.6M$2.54M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$30.2M$17.2M$14.8M$12.6M$2.54M
Total investments$4.13M$0.00$0.00$1.57M$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-7.77M-$-11.76M-$-9.69M-$-7.1M-$-4.18M
Cash flow statement
20252024202320222021
Net income$6.4M$2.37M$2.25M$10M$2.54M
Depreciation and amortization$0.00$0.00$10K$10K$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-13.21M$40K-$-1.2M-$-5.53M$1.65M
Accounts receivable-$-2.59M$820K-$-1.88M$720K-$-720K
Inventory$0.00$0.00$350K-$-350K$0.00
Accounts payable-$-1.63M$800K-$-580K-$-480K$1.89M
Net cash provided by operating activities-$-6.74M$2.08M$900K$4.45M$4.18M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-4.2M$340K$1.73M-$-1.53M$0.00
Common stock issued$7.23M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.95M-$-340K-$-40K$0.00$0.00
Net change in cash-$-3.99M$2.07M$2.59M$2.92M$4.18M
Cash at end of period$7.77M$11.8M$9.69M$7.1M$4.18M
Operating cash flow-$-6.74M$2.08M$900K$4.45M$4.18M
Capital expenditure$0.00$0.00$0.00-$0.00$0.00
Free cash flow-$-6.74M$2.08M$900K$4.45M$4.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Anbio Biotechnology Class A Ordinary Shares

        Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

        CEO
        Michael Lau
        Employees
        27
        Beta
        5.10

        Explore

        Frequently asked questions

        What is the intrinsic value of Anbio Biotechnology Class A Ordinary Shares (NNNN)?

        InvestorsCraft does not currently publish an intrinsic value for NNNN. How the IC value is calculated.

        Is NNNN undervalued?

        InvestorsCraft does not publish an undervaluation signal for NNNN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.